Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.74%
1,091.01
+7.97
+0.74%
—1,083.041,082.631,094.711,080.59——
SIXC
Communications
SIXC
Communications
SIXC
+0.50%
605.40
+3.02
+0.50%
—602.38602.38605.80599.75——
SIXE
Energy
SIXE
Energy
SIXE
+0.96%
1,254.72
+11.89
+0.96%
—1,242.831,229.311,256.581,220.51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.49%
1,756.54
+42.72
+2.49%
—1,713.821,715.471,757.891,715.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.35%
642.22
+2.23
+0.35%
—639.99636.98642.82631.81——
SIXR
Staples
SIXR
Staples
SIXR
+1.27%
848.12
+10.66
+1.27%
—837.46840.30852.15840.30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.21%
216.82
+2.60
+1.21%
—214.22214.22217.26214.05——
SIXT
Technology
SIXT
Technology
SIXT
-0.37%
3,192.57
-11.81
-0.37%
—3,204.383,215.043,215.043,159.90——
SIXU
Utilities
SIXU
Utilities
SIXU
+1.99%
943.81
+18.47
+1.99%
—925.38927.91948.11927.91——
SIXV
Health care
SIXV
Health care
SIXV
+2.13%
1,473.46
+30.75
+2.13%
—1,442.711,443.011,476.181,443.01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.41%
2,370.99
+9.65
+0.41%
—2,361.342,391.002,395.822,354.52——
Q1 2026 earnings • released • EPS beat +11.14% • Revenue beat +5.24%
See results
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$294.90
0.00%
(0.00) 1D
Apr 24, 4:32:38 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
122.63B
Avg. vol.
4.00
Volume
0.00
52-wk high
R$335.20
52-wk low
R$224.65
Shares outstanding
2.04B
No. of employees
32K
News stories
From sources across the web
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com
Last report
Just released
Today, 8:00 AM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
1.58/ (1.42 est.)USD
+11.14%beat
Revenue / Estimate
11.49B/ (10.92B est.)USD
+5.24%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
11.20B
12.27B
12.22B
12.50B
Cost of goods sold
3.02B
3.36B
3.31B
3.51B
Cost of revenue
3.02B
3.36B
3.31B
3.51B
Research and development expenses
2.24B
2.26B
2.43B
2.56B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.58B
1.69B
1.79B
2.09B
Operating expense
4.65B
4.78B
5.05B
5.47B
Total operating expenses
7.66B
8.14B
8.36B
8.98B
Operating income
3.54B
4.13B
3.86B
3.52B
Other non operating income
494.00M
399.00M
529.00M
544.00M
EBT including unusual items
2.97B
1.77B
3.11B
1.47B
EBT excluding unusual items
3.70B
4.22B
4.07B
3.86B
Income tax expense
509.00M
460.00M
919.00M
384.00M
Effective tax rate
17.13%
25.96%
29.51%
26.12%
Other operating expenses
-
-
-
-
Net income
2.46B
1.31B
2.20B
1.09B
Net profit margin
21.93%
10.68%
18.01%
8.69%
Earnings per share
1.80
1.46
1.63
1.26
Interest and investment income
138.00M
139.00M
161.00M
148.00M
Interest expense
-493.00M
-485.00M
-482.00M
-432.00M
Net interest expenses
-355.00M
-346.00M
-321.00M
-284.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.55B
5.12B
4.91B
4.54B
Gain or loss from assets sale
-20.00M
-7.00M
-9.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer